Molecular pathology for classification of tumors and for efficacy prediction of targeted therapies can be a speedily escalating industry.The advice is in part according to new evidence resulting from a systematic assessment of the Cochrane Collaboration [102]. Reviewing the info of RCTs dealing with hypofractionated RT, the authors substantially al